Added Value of Ultrasound-Based Multimodal Imaging to Diagnose Hepatic Sclerosed Hemangioma before Biopsy and Resection

Feiqian Wang(First Affiliated Hospital of Xi'an Jiaotong University), Shin Maeda(University of Tokyo Hospital), Makoto Chuma(Yokohama City University Medical Center), Kazushi Numata(Yokohama City University Medical Center), Masahiro Okada, Masako Otani(Mita Hospital), Mikiko Tanab(Yokohama City University Medical Center), Hiromi Nihonmatsu(Yokohama City University Medical Center), Akito Nozaki(Yokohama City University Medical Center), Wen Luo(Shanghai University), Masayuki Nakano(Nihon University), Naomi Ideno(Yokohama City University Medical Center), Yoshiaki Inayama(Yokohama City University Medical Center), Katsuaki Ogushi(Yokohama City University Medical Center)
Diagnostics
November 16, 2022
10.3390/diagnostics12112818
Cited by 5

Related Papers

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2023|514
Imaging Study of Early Hepatocellular Carcinoma: Usefulness of Gadoxetic Acid–enhanced MR Imaging
|Radiology|2011|354
cHCC‐CCA
|Hepatology|2018|333
Clear Cell Sarcoma of Soft Tissue
|The American Journal of Surgical Pathology|2008|283